Clinical Trial Update: An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone [Phase 3]

View source ↗

Summary

An open-label Phase 3 study evaluated whether switching adults with schizophrenia from risperidone tablets to an equivalent dose of a rapidly-dissolving risperi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Janssen-Ortho Inc., Canada | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED